{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-302580","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-07-14T12:11:11+00:00","discovered_at":"2026-07-14T12:15:00.647924+00:00","generated_at":"2026-07-14T12:15:07.754904+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inhibikase raises $50M through ATM sale of 25M shares to RA Capital for PAH study","bullets":["Sold 25,000,000 shares to RA Capital Management for $50M gross proceeds via ATM facility.","Proceeds will fund operations through topline data readout from Phase 3 IMPROVE-PAH Part B.","Shares sold under effective shelf registration (Form S-3) and ATM prospectus supplement.","Company is clinical-stage developing IKT-001 for Pulmonary Arterial Hypertension."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-302580","json":"https://secwatch.observer/filing/0001193125-26-302580.json","markdown":"https://secwatch.observer/filing/0001193125-26-302580.md","text":"https://secwatch.observer/filing/0001193125-26-302580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/0001193125-26-302580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526302580/d157026d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T12:15:07.754904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}